ATR vs CTSO: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ATR is the larger of the two ($9.05B market cap): the incumbent the market prices for continued execution (23.03x forward earnings, beta 0.32). CTSO is the smaller challenger ($13.85M), priced similarly on forward earnings (∞x): more room to run, but more to prove. If you believe in growth, CTSO fits: analysts expect its revenue to rise 16% next year, against 3% for ATR. If you believe ATR's main driver (High-margin pharma drug delivery) matters more than the growth gap, ATR fits.

ATR vs CTSO: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricATRCTSOWhat it tells you
Market cap$9.05B$13.85MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E23.03∞Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range85% of range11% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how ATR and CTSO affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATR and CTSO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATR and CTSO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AptarGroup (ATR) do?

AptarGroup makes the precision dispensing and drug-delivery systems that sit on top of everyday products: nasal spray and inhaler valves for pharma, pumps and airless systems for fragrance and skincare, and dispensing and non-dispensing closures for food, beverage, personal care, and home care. The company runs three reporting segments (Pharma, Beauty, and Closures), with Pharma generating the bulk of profit thanks to long-cycle, regulated, high-margin drug-delivery contracts. Aptar serves a global customer base and positions itself around active material science and delivery precision rather than commodity packaging.

Full ATR guide

What does CytoSorbents Corporation (CTSO) do?

CytoSorbents makes porous polymer beads packed into cartridges that clip into a blood circuit and pull inflammatory molecules, toxins and some drugs out of a patient's blood. Its main product, CytoSorb, is approved in the European Union and distributed in more than 70 countries, where intensive care units use it in septic shock and cardiac surgeons use it during bypass procedures. The company also owns DrugSorb-ATR, a version aimed at removing the blood thinner Brilinta (ticagrelor) during urgent heart surgery, which is not yet authorized in the United States, and HemoDefend-BGA, an early program meant to make universal plasma. Nearly all revenue comes from outside the U.S.: in the third quarter of 2026 American sales were about $70,000 out of $9.7 million.

Full CTSO guide

ATR vs CTSO: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ATR drivers: High-margin pharma drug delivery; Beauty and consumer recovery.
  • CTSO drivers: Operating cash flow at breakeven; Returning CytoSorb to growth.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Core organic sales were roughly flat early in 2026 and grew 5% in the third quarter, so the question is whether that pickup lasts. For CTSO, financing is still the largest risk, though the November 2026 deal changed its shape.

ATR or CTSO: which should you pick?

If the story you believe is ATR's (High-margin pharma drug delivery), ATR is the more direct way to own it; if it is CTSO's (Operating cash flow at breakeven), CTSO is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATR and CTSO guides.

ATR vs CTSO: the full fundamentals

ATR. At about $143 Aptar trades at about 23 times forward earnings and about 12.7 times EBITDA, a premium to commodity packagers that rests on the pharma franchise and the dividend record; the ~34x trailing figure is distorted by the one-time Russia loss. Analysts see 2026 EPS of about $5.55 before a rebound to about $6.20 in 2027, so the multiple looks reasonable only if that recovery arrives. The tension has shifted from flat organic growth to whether the third quarter's 5% core growth holds.

CTSO. At ~$4.39 the stock trades at roughly 0.4 times trailing sales, a level usually seen in medical device companies with serious balance sheet problems. Earnings ratios do not apply: trailing net loss is ~$16.9 million, much of it from non-cash currency swings and interest, and analysts expect a ~-$3.72 per-share loss for 2026. The November 2026 amendment cut the Avenue loan to ~$12.25 million and moved the maturity to July 2028, so the valuation now rests more on whether a business near cash breakeven with ~73-75% gross margins can grow toward the ~$44 million of 2027 revenue analysts forecast.

Headline figures (approximate, November 2026): ATR shows revenue (ttm) ~$3.99B (Q3 2026 +6% y/y, core +5%), q3 2026 sales / adjusted eps ~$1.02B / $1.52 (vs $1.47 est.), margins (ttm) Gross ~36%, operating ~12.4%, net ~6.7%, net income (ttm) ~$267M (after a $60M Russia deconsolidation loss); CTSO shows revenue (ttm) ~$37.5 million, revenue growth (q3 2026, yoy) ~+2.6%, gross margin (ttm) ~73%, net loss (ttm) ~-$16.9 million.

The bottom line: ATR vs CTSO

ATR and CTSO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ATR and CTSO exposure against your real portfolio. It is not an investment adviser.

Wondering how ATR or CTSO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AptarGroup

Ask Walnut's AI anything about ATR and see how it fits what you own.

FAQ

What is the difference between ATR and CTSO?

+

AptarGroup makes the precision dispensing and drug-delivery systems that sit on top of everyday products: nasal spray and inhaler valves for pharma, pumps and airless systems for fragrance and skincare, and dispensing and non-dispensing closures for food, beverage, personal care, and home care. CytoSorbents makes porous polymer beads packed into cartridges that clip into a blood circuit and pull inflammatory molecules, toxins and some drugs out of a patient's blood. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ATR or CTSO the better stock?

+

Neither is universally better. ATR is the larger incumbent; CTSO is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ATR or CTSO?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ATR and CTSO?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ATR vs CTSO?

+

ATR: Core organic sales were roughly flat early in 2026 and grew 5% in the third quarter, so the question is whether that pickup lasts. The planned decline in emergency medicine dispensing sales (about $65 million in 2026) is a known drag on the otherwise strong pharma segment, which grew only 1% on a core basis in the third quarter. Beauty and closures are exposed to consumer discretionary weakness, customer destocking, and input-cost swings. The Russian subsidiary has now been deconsolidated at a $60.4 million after-tax cost, removing that business from results. Net debt of about $1.2 billion is moderate. At about 34 times trailing reported earnings (inflated by the Russia charge) and 23 times forward, after a ~13% one-month rally, the stock is not cheap for a mid-single-digit organic grower, and currency translation adds volatility given the company's large international footprint. CTSO: Financing is still the largest risk, though the November 2026 deal changed its shape. Avenue Capital debt fell from ~$17.5 million to ~$12.25 million, interest-only payments were extended to March 31, 2028 (three more months if DrugSorb-ATR is approved by then) and maturity moved to July 1, 2028; the company puts interest savings at ~$0.7 million over twelve months. Avenue can now convert up to ~$3.0 million of principal at $6.916 a share, and another ~$3.125 million at $8.645 from the earlier of DrugSorb-ATR approval or January 1, 2028, so further dilution is built in. Most of the ~$4.0 million of new cash went to repaying ~$3.0 million of principal plus fees, which leaves the company relying on breakeven operations. Listing is the second risk: the market value is far below Nasdaq's $35 million minimum, the December 28, 2026 deadline is close, and the new shares add equity but the company itself says there is no assurance it keeps the listing. Accounting is a third: material weaknesses persist, and the Q3 10-Q was filed late after a currency loss error; the first release understated nine-month net loss by ~$0.6 million. Regulatory risk remains, because the FDA has already turned down DrugSorb-ATR once, and the business depends heavily on German and European hospital budgets.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ATR or CTSO; figures are approximate and dated (as of November 2026). Verify current data before investing.